164 related articles for article (PubMed ID: 28440785)
1. Impacts of HBV rtH55R polymerase substitution on viral replication and rtM204I/V resistance to nucleoside/nucleotide antiviral drugs.
Xiang KH; Zhao CY; Wang S; Li Y; Su MZ; Wang QY; Xu XZ; Deng J; Zhuang H; Li T
Antivir Ther; 2018; 23(1):33-42. PubMed ID: 28440785
[TBL] [Abstract][Full Text] [Related]
2. The rtL229 substitutions in the reverse transcriptase region of hepatitis B virus (HBV) polymerase are potentially associated with lamivudine resistance as a compensatory mutation.
Ji D; Liu Y; Li L; Xu Z; Si LL; Dai JZ; Li X; Wang L; Yao Z; Xin SJ; Chen GF; Xu D
J Clin Virol; 2012 May; 54(1):66-72. PubMed ID: 22398037
[TBL] [Abstract][Full Text] [Related]
3. Investigation into drug-resistant mutations of HBV from 845 nucleoside/nucleotide analogue-naive Chinese patients with chronic HBV infection.
Li X; Liu Y; Zhao P; Wang Y; Chen L; Xin S; Zhang XX; Xu D
Antivir Ther; 2015; 20(2):141-7. PubMed ID: 24992206
[TBL] [Abstract][Full Text] [Related]
4. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine.
Tenney DJ; Levine SM; Rose RE; Walsh AW; Weinheimer SP; Discotto L; Plym M; Pokornowski K; Yu CF; Angus P; Ayres A; Bartholomeusz A; Sievert W; Thompson G; Warner N; Locarnini S; Colonno RJ
Antimicrob Agents Chemother; 2004 Sep; 48(9):3498-507. PubMed ID: 15328117
[TBL] [Abstract][Full Text] [Related]
5. Impact of the rtI187V polymerase substitution of hepatitis B virus on viral replication and antiviral drug susceptibility.
Fan J; Wang Y; Xiong H; Guo X; Cheng YC
J Gen Virol; 2014 Nov; 95(Pt 11):2523-2530. PubMed ID: 25028473
[TBL] [Abstract][Full Text] [Related]
6. Genotype-specific mutations in the polymerase gene of hepatitis B virus potentially associated with resistance to oral antiviral therapy.
Mirandola S; Sebastiani G; Rossi C; Velo E; Erne EM; Vario A; Tempesta D; Romualdi C; Campagnolo D; Alberti A
Antiviral Res; 2012 Dec; 96(3):422-9. PubMed ID: 23026293
[TBL] [Abstract][Full Text] [Related]
7. Entecavir allows an unexpectedly high residual replication of HBV mutants resistant to lamivudine.
Geipel A; Seiz PL; Niekamp H; Neumann-Fraune M; Zhang K; Kaiser R; Protzer U; Gerlich WH; Glebe D;
Antivir Ther; 2015; 20(8):779-87. PubMed ID: 25560463
[TBL] [Abstract][Full Text] [Related]
8. Development of peptide nucleic acid mediated polymerase chain reaction clamping (PMPC)--direct sequencing method for detecting lamivudine-resistant hepatitis B virus (HBV) variants with high sensitivity and specificity.
Ogata N; Ichida T; Aoyagi Y; Kitajima I
Rinsho Byori; 2003 Apr; 51(4):313-9. PubMed ID: 12747252
[TBL] [Abstract][Full Text] [Related]
9. Identification of hepatitis B virus rtS117F substitution as a compensatory mutation for rtM204I during lamivudine therapy.
Lin CL; Chien RN; Hu CC; Lai MW; Yeh CT
J Antimicrob Chemother; 2012 Jan; 67(1):39-48. PubMed ID: 22001270
[TBL] [Abstract][Full Text] [Related]
10. Emergence of hepatitis B virus quasispecies with lower susceptibility to nucleos(t)ide analogues during lamivudine treatment.
Moriconi F; Colombatto P; Coco B; Ciccorossi P; Oliveri F; Flichman D; Maina AM; Sacco R; Bonino F; Brunetto MR
J Antimicrob Chemother; 2007 Aug; 60(2):341-9. PubMed ID: 17567633
[TBL] [Abstract][Full Text] [Related]
11. Tenofovir is a more suitable treatment than entecavir for chronic hepatitis B patients carrying naturally occurring rtM204I mutations.
Choe WH; Kim K; Lee SY; Choi YM; Kwon SY; Kim JH; Kim BJ
World J Gastroenterol; 2019 Sep; 25(33):4985-4998. PubMed ID: 31543688
[TBL] [Abstract][Full Text] [Related]
12. Profile of HBV antiviral resistance mutations with distinct evolutionary pathways against nucleoside/nucleotide analogue treatment among Chinese chronic hepatitis B patients.
Yang JX; Liu BM; Li XG; Yan CH; Xu J; Sun XW; Wang YH; Jiao XJ; Yan L; Dong JP; Hou CS; Abuduheilili X; Li T; Zhuang H
Antivir Ther; 2010; 15(8):1171-8. PubMed ID: 21149924
[TBL] [Abstract][Full Text] [Related]
13. Changes in viral loads of lamivudine-resistant mutants and evolution of HBV sequences during adefovir dipivoxil therapy.
Suzuki F; Kumada H; Nakamura H
J Med Virol; 2006 Aug; 78(8):1025-34. PubMed ID: 16789011
[TBL] [Abstract][Full Text] [Related]
14. The L80I substitution in the reverse transcriptase domain of the hepatitis B virus polymerase is associated with lamivudine resistance and enhanced viral replication in vitro.
Warner N; Locarnini S; Kuiper M; Bartholomeusz A; Ayres A; Yuen L; Shaw T
Antimicrob Agents Chemother; 2007 Jul; 51(7):2285-92. PubMed ID: 17438047
[TBL] [Abstract][Full Text] [Related]
15. Increased occurrence of mutant rtI233V of HBV in patients receiving adefovir therapy.
Liu Y; Xin S; Ye X; Chen R; Xu Z; Li X; Ye H; Cheng S; Xu D
Antivir Ther; 2016; 21(1):9-16. PubMed ID: 26079809
[TBL] [Abstract][Full Text] [Related]
16. Acute hepatitis B infection associated with drug-resistant hepatitis B virus.
Xu Z; Liu Y; Xu T; Chen L; Si L; Wang Y; Ren X; Zhong Y; Zhao J; Xu D
J Clin Virol; 2010 Aug; 48(4):270-4. PubMed ID: 20580309
[TBL] [Abstract][Full Text] [Related]
17. High frequency of complex mutational patterns in lamivudine resistant hepatitis B virus isolates.
Neumann-Fraune M; Beggel B; Pfister H; Kaiser R; Verheyen J
J Med Virol; 2013 May; 85(5):775-9. PubMed ID: 23408582
[TBL] [Abstract][Full Text] [Related]
18. In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir.
Lada O; Benhamou Y; Cahour A; Katlama C; Poynard T; Thibault V
Antivir Ther; 2004 Jun; 9(3):353-63. PubMed ID: 15259898
[TBL] [Abstract][Full Text] [Related]
19. Higher detection rates of amino acid substitutions in HBV reverse transcriptase/surface protein overlapping sequence is correlated with lower serum HBV DNA and HBsAg levels in HBeAg-positive chronic hepatitis B patients with subgenotype B2.
Su M; Xiang K; Li Y; Li Y; Deng J; Xu X; Yan L; Zhuang H; Li T
Infect Genet Evol; 2016 Jun; 40():275-281. PubMed ID: 27006281
[TBL] [Abstract][Full Text] [Related]
20. Impact of hepatitis B e antigen-suppressing mutations on the replication efficiency of entecavir-resistant hepatitis B virus strains.
Amini-Bavil-Olyaee S; Herbers U; Luedde T; Trautwein C; Tacke F
J Viral Hepat; 2011 Nov; 18(11):804-14. PubMed ID: 20887378
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
